NYSEAMERICAN:AZTR Azitra Q1 2026 Earnings Report $0.17 0.00 (-2.25%) Closing price 09/18/2026 04:10 PM EasternExtended Trading$0.18 +0.00 (+2.30%) As of 09/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Azitra EPS ResultsActual EPS-$0.25Consensus EPS -$0.01Beat/MissMissed by -$0.24One Year Ago EPSN/AAzitra Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAzitra Announcement DetailsQuarterQ1 2026Date5/13/2026TimeBefore Market OpensConference Call DateWednesday, May 13, 2026Conference Call Time8:00AM ETUpcoming EarningsAzitra's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Azitra Earnings HeadlinesAzitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | prnewswire.comAzitra, Inc. Regains Compliance with NYSE American Continued Listing StandardsAugust 21, 2026 | prnewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 19 at 1:00 AM | Profits Run (Ad)Azitra, Inc. Announces Q2 2026 Results and Provides Business UpdatesAugust 12, 2026 | prnewswire.comAzitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and ElasticityJuly 15, 2026 | prnewswire.comAzitra Expands Authorized Shares Following Stockholder ApprovalsJune 18, 2026 | theglobeandmail.comSee More Azitra Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email. Email Address About AzitraAzitra (NYSEAMERICAN:AZTR) is a clinical-stage biotechnology company focused on developing precision dermatology treatments for inflammatory and other skin conditions. The company uses engineered microbes and its proprietary platform to discover and develop live biotherapeutic products intended to address disease-related changes in the skin microbiome and deliver therapeutic proteins locally. Azitra’s product pipeline has included ATR-12, an engineered strain of Staphylococcus epidermidis designed to produce filaggrin-1 for the potential treatment of Netherton syndrome, a rare genetic skin disorder. The company has also developed ATR-04, a topical live biotherapeutic candidate intended to help treat acneiform rash and other skin complications associated with epidermal growth factor receptor inhibitor therapies. Founded in 2014, Azitra is based in Branford, Connecticut, and conducts its research and development activities in the United States. Its programs are aimed at addressing both rare dermatologic diseases and more common treatment-related skin conditions.View Azitra ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
